轻型卒中：溶栓还是不溶栓？

doi:10.3969/j.issn.1673-5765.2023.01.012

摘要/Abstract

摘要： 轻型卒中的定义及诊断标准尚不统一，其是否都需要溶栓尚存在争议。轻型卒中在我国卒中患者中的比例有逐年增加的趋势，虽然有基于氯吡格雷用于急性非致残性脑血管病事件高危人群（clopidogrel in high-risk patients with acute non-disabling cerebrovascular events，CHANCE）系列研究抗血小板治疗的循证医学证据，但仍有30%的患者预后不良，由此带来的疾病负担仍然很重。当前指南对于发病4.5 h内的轻型致残性卒中推荐静脉溶栓治疗，而对于轻型非致残性卒中意见不一。近年的研究显示，对于轻型卒中合并大血管闭塞患者，早期包括静脉溶栓在内的积极再灌注治疗可能会给患者带来功能获益。本文对轻型卒中溶栓相关研究进行综述，期待未来有更多的设计严谨的大型试验来评估溶栓治疗在轻型卒中患者中的有效性和安全性。

文章导读： 轻型卒中患者比例有逐年升高趋势且预后不佳，目前轻型卒中超早期静脉溶栓治疗的有效性和安全性仍存在争议，期待高质量的随机对照试验提供更多证据。

关键词: 轻型卒中; 溶栓治疗; 阿替普酶; 替奈普酶; 预后

Abstract: The definition and diagnostic criteria of minor stroke are not unified until now, and it is still controversial whether all patients with acute minor stroke need intravenous thrombolysis. The proportion of minor stroke patients in China has an increasing trend year by year. Although the CHANCE (clopidogrel in high-risk patients with acute non-disabling cerebrovascular events) trial and other studies have showed that antiplatelet therapy is effective for minor stroke, there are still approximately 30% of patients with poor functional outcomes and the burden of disease is very heavy. The current guidelines recommended intravenous alteplase administration within 4.5 hours for patients with disabling minor stroke but not for nondisabling minor stroke. Recent studies showed that reperfusion therapy including intravenous thrombolysis might be beneficial for patients with minor stroke and large vessel occlusion. This article reviewed the advances in thrombolytic therapy for minor stroke, to provide reference for clinical treatment and relevant research in minor stroke.

Key words: Minor stroke; Thrombolytic therapy; Alteplase; Tenecteplase; Prognosis

段春苗, 熊云云, 王拥军. 轻型卒中：溶栓还是不溶栓？[J]. 中国卒中杂志, 2023, 18(01): 107-113.

DUAN Chunmiao, XIONG Yunyun, WANG Yongjun. Thrombolysis or Not Thrombolysis for Minor Stroke?[J]. Chinese Journal of Stroke, 2023, 18(01): 107-113.

参考文献

[1] WANG Y J，LI Z X，GU H Q，et al. China stroke statistics：an update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases，China National Clinical Research Center for Neurological Diseases，the Chinese Stroke Association，National Center for Chronic and Non-communicable Disease Control and Prevention，Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations[J]. Stroke Vasc Neurol，2022，7（5）：415-450.
[2] DHAMOON M S，MOON Y P，PAIK M C，et al. Long-term functional recovery after first ischemic stroke：the Northern Manhattan study[J]. Stroke，2009，40（8）：2805-2811.
[3] REEVES M，KHOURY J，ALWELL K，et al. Distribution of national institutes of health stroke scale in the Cincinnati/Northern Kentucky stroke study[J]. Stroke，2013，44（11）：3211-3213.
[4] LI Z X，WANG C J，ZHAO X Q，et al. Substantial progress yet significant opportunity for improvement in stroke care in China[J]. Stroke，2016，47（11）：2843-2849.
[5] LI L，PAN Y S，WANG M X，et al. Trends and predictors of myocardial infarction or vascular death after ischaemic stroke or TIA in China，2007-2018：insights from China national stroke registries[J]. Stroke Vasc Neurol，2021，6（2）：214-221.
[6] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2022-07-22]. https://doi.org/10.1161/STR.0000000000000375.
[7] KIRCHHOF P，BENUSSI S，KOTECHA D，et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J，2016，37（38）：2893-2962.
[8] SMITH E E，FONAROW G C，REEVES M J，et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator：findings from get with the guidelines-stroke[J]. Stroke，2011，42（11）：3110-3115.
[9] ROMANO J G，GARDENER H，CAMPO-BUSTILLO I，et al. Predictors of outcomes in patients with mild ischemic stroke symptoms：MaRISS[J]. Stroke，2021，52（6）：1995-2004.
[10] TAN Y，PAN Y S，LIU L P，et al. One-year outcomes and secondary prevention in patients after acute minor stroke：results from the China national stroke registry[J]. Neurol Res，2017，39（6）：484-491.
[11] EMBERSON J，LEES K R，LYDEN P，et al. Effect of treatment delay，age，and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke：a meta-analysis of individual patient data from randomised trials[J]. Lancet，2014，384（9958）：1929-1935.
[12] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[13] SABER H，KHATIBI K，SZEDER V，et al. Reperfusion therapy frequency and outcomes in mild ischemic stroke in the United States[J]. Stroke，2020，51（11）：3241-3249.
[14] XIONG Y Y，YAN R，GU H Q，et al. Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke[J/OL]. Ann Transl Med，2021，9（9）：767[2022-07-02]. https://doi.org/10.21037/atm-21-40.
[15] ASDAGHI N，WANG K，CILIBERTI-VARGAS M A，et al. Predictors of thrombolysis administration in mild stroke：florida-puerto rico collaboration to reduce stroke disparities[J]. Stroke，2018，49（3）：638-645.
[16] HARBISON J W. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the ticlopidine aspirin stroke study[J]. Stroke，1992，23（12）：1723-1727.
[17] NORRVING B，CRONQVIST S. Clinical and radiologic features of lacunar versus nonlacunar minor stroke[J]. Stroke，1989，20（1）：59-64.
[18] OLSSON J E，MÜLLER R，BERNELI S. Long-term anticoagulant therapy for TIAs and minor strokes with minimum residuum[J]. Stroke，1976，7（5）：444-451.
[19] FISCHER U，BAUMGARTNER A，ARNOLD M，et al. What is a minor stroke?[J]. Stroke，2010，41（4）：661-666.
[20] POST P N，STIGGELBOUT A M，WAKKER P P. The utility of health states after stroke：a systematic review of the literature[J]. Stroke，2001，32（6）：1425-1429.
[21] CRESPI V，BRAGA M，BERETTA S，et al. A practical definition of minor stroke[J]. Neurol Sci，2013，34（7）：1083-1086.
[22] KHATRI P，CONAWAY M R，JOHNSTON K C，et al. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke[J]. Stroke，2012，43（2）：560-562.
[23] ROMANO J G，SMITH E E，LIANG L，et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis：a retrospective analysis of the get with the guidelines-stroke registry[J]. JAMA Neurol，2015，72（4）：423-431.
[24] JOHNSTON S C，AMARENCO P，ALBERS G W，et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack[J]. N Engl J Med，2016，375（1）：35-43.
[25] JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[26] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[27] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.
[28] JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[29] XIONG Y Y，GU H Q，ZHAO X Q，et al. Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke：from a large-scale nation-wide longitudinal registry[J]. Stroke，2021，52（4）：1253-1258.
[30] TORRES-MOZQUEDA F，HE J，YEH I B，et al. An acute ischemic stroke classification instrument that includes CT or MR angiography：the Boston acute stroke imaging scale[J]. AJNR Am J Neuroradiol，2008，29（6）：1111-1117.
[31] National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group. Recombinant tissue plasminogen activator for minor strokes：the National Institute of Neurological Disorders and Stroke rt-PA stroke study experience[J]. Ann Emerg Med，2005，46（3）：243-252.
[32] KHATRI P，TAYAMA D，COHEN G，et al. Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the third international stroke trial-3：post hoc analysis[J]. Stroke，2015，46（8）：2325-2327.
[33] CHOI J C，JANG M U，KANG K，et al. Comparative effectiveness of standard care with Ⅳ thrombolysis versus without Ⅳ thrombolysis for mild ischemic stroke[J/OL]. J Am Heart Assoc，2015，4（1）：e001306[2022-07-02]. https://doi.org/10.1161/JAHA.114.000596.
[34] KHATRI P，KLEINDORFER D O，DEVLIN T，et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits：the PRISMS randomized clinical trial[J]. JAMA，2018，320（2）：156-166.
[35] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2022-07-02]. https://doi.org/10.1161/STR.0000000000000211.
[36] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J/OL]. Eur Stroke J，2021，6（1）：I-LXII[2022-07-02]. https://doi.org/10.1177/2396987321989865.
[37] 刘丽萍，陈玮琪，段婉莹，等. 中国脑血管病临床管理指南（节选版）：缺血性脑血管病临床管理[J]. 中国卒中杂志，2019，14（7）：709-726.
[38] HELDNER M R，ZUBLER C，MATTLE H P，et al. National institutes of health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke[J]. Stroke，2013，44（4）：1153-1157.
[39] MAZYA M V，COORAY C，LEES K R，et al. Minor stroke due to large artery occlusion. When is intravenous thrombolysis not enough? Results from the SITS international stroke thrombolysis register[J]. Eur Stroke J，2018，3（1）：29-38.
[40] KIM J T，PARK M S，CHANG J，et al. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke[J/OL]. PLoS One，2013，8（8）：e70996[2022-07-02]. https://doi.org/10.1371/journal.pone.0070996.
[41] GWAK D S，KWON J A，SHIM D H，et al. Perfusion and diffusion variables predict early neurological deterioration in minor stroke and large vessel occlusion[J]. J Stroke，2021，23（1）：61-68.
[42] ZHONG W S，ZHOU Y，ZHANG K M，et al. Minor non-disabling stroke patients with large vessel severe stenosis or occlusion might benefit from thrombolysis[J/OL]. Brain Sci，2021，11（7）：945[2022-07-02]. https://doi.org/10.3390/brainsci11070945.
[43] TSIVGOULIS G，GOYAL N，KATSANOS A H，et al. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity[J]. Eur J Neurol，2020，27（6）：1039-1047.
[44] SENERS P，PERRIN C，LAPERGUE B，et al. Bridging therapy or Ⅳ thrombolysis in minor stroke with large vessel occlusion[J]. Ann Neurol，2020，88（1）：160-169.
[45] SENERS P，DARGAZANLI C，PIOTIN M，et al. Intended bridging therapy or intravenous thrombolysis alone in minor stroke with basilar artery occlusion[J]. Stroke，2021，52（2）：699-702.
[46] WU X，KHUNTE M，PAYABVASH S，et al. Outcomes after thrombectomy for minor stroke：a meta-analysis[J/OL]. World Neurosurg，2021，149：e1140-e1154[2022-07-02]. https://doi.org/10.1016/j.wneu.2020.12.047.
[47] FEIL K，MATUSEVICIUS M，HERZBERG M，et al. Minor stroke in large vessel occlusion：a matched analysis of patients from the German stroke registry-endovascular treatment（GSR-ET）and patients from the safe implementation of treatments in stroke-international stroke thrombolysis register（SITS-ISTR）[J]. Eur J Neurol，2022，29（6）：1619-1629.
[48] SENERS P，ARQUIZAN C，FONTAINE L，et al. Perfusion imaging and clinical outcome in acute minor stroke with large vessel occlusion[J]. Stroke，2022，53（11）：3429-3438.
[49] KEYT B A，PAONI N F，REFINO C J，et al. A faster-acting and more potent form of tissue plasminogen activator[J]. Proc Natl Acad Sci U S A，1994，91（9）：3670-3674.
[50] COUTTS S B，DUBUC V，MANDZIA J，et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion[J]. Stroke，2015，46（3）：769-774.
[51] SYKORA M，KREBS S，SIMADER F，et al. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1[J].Int J Stroke，2022，17（1）：109-119.